A standardized treat-to-target (T2T) strategy works just as well in elderly-onset rheumatoid arthritis (RA) as it does in younger patients — and older patients may actually need less intensive treatment. A Dutch post hoc analysis found similar disease activity and safety profiles across age groups, with elderly-onset patients less likely to need biologic DMARDs and more likely to achieve drug-free remission at 2 years.
A new study out of the Netherlands suggests that elderly patients newly diagnosed with rheumatoid arthritis (RA) can be successfully managed using the same treat-to-target (T2T) approach used in younger patients — and may actually fare better in some respects. The post hoc analysis of the tREACH trial followed 425 RA patients over 2 years, comparing 98 with elderly-onset disease (age >65) to 327 with young-onset disease (ages 18–65).
Both groups showed similar disease activity trajectories and comparable safety profiles. Notably, older patients required less aggressive therapy and were more likely to be completely off disease-modifying antirheumatic drugs (DMARDs) by the end of the study period.
By the Numbers:
Why it matters: RA is often undertreated in older adults due to concerns about drug tolerability and complexity. This study provides reassuring evidence that a structured T2T strategy is both safe and effective in elderly-onset RA, potentially improving outcomes for a population that has historically been underrepresented in clinical trials.
